Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW7VGZ)

Drug Name
PegCNTF Drug Info
Synonyms
Piperidine, 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-; Sch-37370; 117796-52-8; Sch 37370; UNII-GA60WRR45J; N-Acetyldesloratadine; GA60WRR45J; CHEMBL10971; RESPATADINE; ethanone, 1-[4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinyl]-; AC1L1TPN; AC1Q5KQ9; SCHEMBL3071641; GTPL1853; DTXSID10151911; FLTBEMVEAFMWDD-UHFFFAOYSA-N; ZINC596712; BDBM50007473; 1-Acetyl-4-(8-chloro-5,6-dihydro-11H-benzo(5,6)cycloheptal(1,2-b)pyridin-11-ylidine)piperidine; SCH-37370
Indication
Disease Entry ICD 11 Status REF
Obesity 5B81 Phase 1 [1]
Cross-matching ID
PubChem CID
60680
CAS Number
CAS 117796-52-8
TTD Drug ID
DMW7VGZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Ciliary neurotrophic factor receptor alpha (CNTFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NT-501 DM4H78P Ocular inflammation 9C61.24 Phase 2/3 [3]
Drug(s) Targeting Platelet-activating factor receptor (PTAFR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ticlopidine DMO946V Acute coronary syndrome BA41 Approved [4]
RUPATADINE DMBPN7T N. A. N. A. Phase 4 [5]
ISRAPAFANT DMP61YB Asthma CA23 Phase 3 [6]
CMI-392 DM1NCUY Psoriasis vulgaris EA90 Phase 2 [7]
Lexipafant DMZ2YBE Nerve injury ND56.4 Phase 2 [8]
YM-264 DMAZNVX Sepsis 1G40-1G41 Phase 2 [9]
Dersalazine DMH96JW Inflammatory bowel disease DD72 Phase 2 [10]
60P002 DMHBN8X Dengue 1D20-1D2Z Phase 2 [11]
FOROPAFANT DML1DGP Asthma CA23 Discontinued in Phase 3 [12]
BN 50730 DMZK70E Asthma CA23 Discontinued in Phase 3 [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Ciliary neurotrophic factor receptor alpha (CNTFR) TTT2F9E CNTFR_HUMAN Agonist [1]
Platelet-activating factor receptor (PTAFR) TTQL5VC PTAFR_HUMAN Modulator [2]

References

1 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
2 Sch 37370: a new drug combining antagonism of platelet-activating factor (PAF) with antagonism of histamine. Agents Actions Suppl. 1991;34:313-21.
3 Clinical pipeline report, company report or official report of Neurotech.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
6 Amino acid residues critical for endoplasmic reticulum export and trafficking of platelet-activating factor receptor. J Biol Chem. 2010 Feb 19;285(8):5931-40.
7 Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor. Pharmacol Res. 2001 Sep;44(3):213-20.
8 Lexipafant and acute pancreatitis: a critical appraisal of the clinical trials.Eur J Surg.2002;168(4):215-9.
9 Effects of YM264, a novel PAF antagonist, on puromycin aminonucleoside-induced nephropathy in the rat. Biochem Biophys Res Commun. 1991 Apr 30;176(2):781-5.
10 The intestinal anti-inflammatory effect of dersalazine sodium is related to a down-regulation in IL-17 production in experimental models of rodent colitis. Br J Pharmacol. 2012 February; 165(3): 729-740.
11 Clinical pipeline report, company report or official report of 60 Degrees Pharmaceuticals.
12 Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51.
13 Platelet-activating factor antagonist BN 50730 attenuates hypoxic-ischemic brain injury in neonatal rats. Pediatr Res. 2001 Jun;49(6):804-11.